Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus serplulimab and nab-paclitaxel + cisplatin as neoadjuvant therapy for locally advanced esophageal cancer
ChiCTR2400082050Phase 2Recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab, paclitaxel and cisplatin in esophageal cancer, sponsored by Dongguan People's Hospital. Primary endpoints: Complete pathological response rate and Feasibility of neoadjuvant therapy completion. Started Mar 2024; status: recruiting.
02
Drugs
serplulimabpaclitaxelcisplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2400082050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082050.